Showing results (511-520 of 630) with videos related to
Sort By:
Pageof 63
Journal of the American Academy of Dermatology|January 9, 2023
Executive summary: American Academy of Dermatology guidelines of care for the management of atopic dermatitis in adults with topical therapiesRobert Sidbury, Ali Alikhan, Lionel Bercovitch, et al.The British Journal of Dermatology|February 22, 2019
Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trialsJ I Silverberg, E L Simpson, M Ardeleanu, et al.Journal of the American Academy of Dermatology|November 9, 2023
Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapiesDawn M R Davis, Aaron M Drucker, Ali Alikhan, et al.Journal of the American Academy of Dermatology|February 8, 2018
Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose studyEmma Guttman-Yassky, Jonathan I Silverberg, Osamu Nemoto, et al.Journal of the American Academy of Dermatology|January 31, 2024
Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trialEric L Simpson, Jonathan I Silverberg, Margitta Worm, et al.Journal of the American Academy of Dermatology|November 9, 2023
Executive summary: Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapiesDawn M R Davis, Aaron M Drucker, Ali Alikhan, et al.Journal of the American Academy of Dermatology|January 14, 2023
Guidelines of care for the management of atopic dermatitis in adults with topical therapiesRobert Sidbury, Ali Alikhan, Lionel Bercovitch, et al.The British Journal of Dermatology|March 30, 2023
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trialsAndrew Blauvelt, Jacob P Thyssen, Emma Guttman-Yassky, et al.Journal of the American Academy of Dermatology|April 8, 2026
Guidelines of care for the management of atopic dermatitis in pediatric patientsDawn M R Davis, Ali Alikhan, Lionel Bercovitch, et al.British Journal of Clinical Pharmacology|January 15, 2026
Model-informed drug development to support nemolizumab clinical development in adults and adolescents with moderate to severe atopic dermatitisFloris Fauchet, Anna Largajolli, Petra M Jauslin, et al.Pageof 63